KOSPI Eyes Best Weekly Gain Since June as Samsung, SK Hynix Rally 
Pandora Shares Rise as Q2 Results Beat Forecasts, 2026 Outlook Raised 
Thyssenkrupp Raises 2026 Profit Outlook as Steel and Materials Units Strengthen 
Stripe, Advent Reportedly Pursue $53 Billion PayPal Takeover 
Nvidia Eyes $3 Billion Investment in SoftBank-Backed AI Data Center 
Lenovo Revenue Surges 43% as AI Demand Drives Record First-Quarter Growth 
Australia’s Corporate Leaders Face Parliament Over KPMG Client Data Scandal 
Asian Currencies Edge Higher as Soft US Inflation Weighs on Dollar 
Tesla Roadster Reveal Could Feature SpaceX Thrusters in August 
Asian Currencies Steady Ahead of US CPI as Oil Prices Rise 
Strait of Hormuz Shipping Near Standstill After New Vessel Attacks 
Paramount Skydance Clears Regulatory Hurdles for Warner Bros. Discovery Deal 
Wall Street Hits Record High as Softer Inflation Data Eases Fed Rate Hike Fears 
Trump Imposes New US Tariffs on Drone Imports Over National Security Concerns 
US Dollar Slips as Weak Retail Sales Reduce Fed Rate Hike Bets 
Asian Stocks Rise as AI Chip Rally Lifts South Korea, Japan 
Cisco Forecasts Strong Fiscal 2027 Growth as AI Networking Demand Surges 
Add as a preferred source on Google
SK Plasma Co. Ltd. is building a new blood product plant with an investment of KRW300 billion or about $250 million. The facility is set to be constructed in Indonesia.
Once in full operation, the new plant is expected to have the capacity to produce one million liters of blood products per year. SK Plasma will break ground some time this year, and the plant will be completed in two years.
Business insiders revealed earlier this week that the South Korean firm that produces albumin, immunoglobulin, coagulation factors, and antithrombin received the final approval for the construction of its plant from the Ministry of Health and Welfare of Indonesia not long ago. The facility will process the collected blood plasma and turn them into therapeutic agents.
Business Korea reported that for this project, SK Plasma would partner with Infion through a joint venture (JV) agreement. It is an Indonesian pharmaceutical company that will SK Plasma with its business operation in the country.
The size of the company’s upcoming plant in Indonesia is said to have a bigger production capacity than its facility in Andong, South Korea. It will offer 1.6 times more than the 600,000-liter capacity of its Korean plant.
In any case, the new factory will produce six types of blood products like Liv Gamma and albumin. The Korea Herald reported that albumin and immune globulin, which will be produced at the SK Plasma Indonesian facility, are typically used for patients with hemophilia and immunodeficiency diseases. These are made through strict and rigorous processes, including the centrifugation of blood collected from blood donation drives.
The blood products will ensure a stable supply in Indonesia, where the population is already close to 300 million. It was said that 100% of the citizens are currently dependent on imports of blood products.
“By transferring technologies relating to blood products and installing a manufacturing facility in a country that has no related infrastructure, SK Plasma seeks to create new business opportunities and reach the company’s ESG goals,” Kim Seung Joo, SK Plasma’s chief executive officer, said in a statement.
